科兴制药2025年营收15.41亿元，净利润1.59亿元同比增406.47%

Group 1 - The core viewpoint of the news is that Sinovac Biotech reported a significant increase in revenue and net profit for the year 2025, driven by strong overseas market expansion [1] - The company's revenue reached 1.541 billion yuan, representing a year-on-year growth of 9.54%, while the net profit attributable to shareholders surged by 406.47% to 159 million yuan [1] - The growth was primarily attributed to the robust development in overseas markets, with products now covering approximately 70 countries and regions, particularly performing well in the European Union [1] Group 2 - On February 25, 2026, Sinovac Biotech announced that its wholly-owned subsidiary, Shenzhen Sinovac Pharmaceutical, received clinical trial approval for the GB19 injection, targeting systemic lupus erythematosus and other autoimmune diseases [2] - The GB19 injection is based on an innovative mechanism targeting BDCA2, with preclinical studies demonstrating excellent safety and bioavailability [2] - This approval marks an important strategic move for the company in the autoimmune disease sector, potentially enriching its product pipeline in the future [2] Group 3 - In the past week (as of February 27, 2026), Sinovac Biotech's stock price increased by 1.42%, with a trading range fluctuation of 2.52%, closing at 30.63 yuan, up by 0.56% on the day [3] - On February 27, there was a net inflow of 933,900 yuan in main funds, although the overall trend over the past five days showed a net outflow [3] - The turnover rate was 0.55%, with a trading volume of 33.7 million yuan, indicating relatively stable market activity [3]